We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




AI Model Accurately Shows Presence and Location of Cancer in Pathological Images

By LabMedica International staff writers
Posted on 15 Aug 2022
Print article
Image: AI model reduces cost and time and increasing accuracy of cancer diagnosis (Photo courtesy of Pexels)
Image: AI model reduces cost and time and increasing accuracy of cancer diagnosis (Photo courtesy of Pexels)

It is usually necessary to accurately mark the location of the cancer site in pathological images to solve the problems involved with zoning that indicates the location information of cancer, which takes a long time and therefore increased cost. Existing deep learning models need to construct a dataset, in which the location of the cancer was accurately drawn, to specify the cancer site. Now, researchers have developed a weakly supervised deep learning model that can accurately show the presence and location of cancer in pathological images based only on data where the cancer is present. The deep learning model improves efficiency and is expected to make a significant contribution to the relevant research field.

Scientists at Daegu Gyeongbuk Institute of Science and Technology (DGIST, Daegu, Korea) developed the weakly supervised learning model that zones cancer sites with only rough data such as 'whether the cancer in the image is present or not' is under active study. However, there would be a significant deterioration in performance if the existing weakly supervised learning model is applied to a huge pathological image dataset where the size of one image is as large as a few gigabytes. To solve this problem, the researchers attempted to improve performance by dividing the pathological image into patches, although the divided patches lose the correlation between the location information and each split data, which means that there is a limit to using all of the available information.

In response, the research team discovered a technique of segmenting down to the cancer site solely based on the learned data indicating the presence of cancer by slide. The team developed a pathological image compression technology that first teaches the network to effectively extract significant features from the patches through unsupervised contrastive learning and uses this to detect the main features while maintaining each location information to reduce the size of the image while maintaining the correlation between the patches. Later, the team developed a model that can find the regions that are highly likely to have cancer from the compressed pathology images by using a class activation map and zone all of these regions from the entire pathology images using a pixel correlation module (PCM). The newly developed deep learning model showed a dice similarity coefficient (DSC) score of up to 81-84 only with the learning data with slide-level cancer labels in the cancer zoning problem. It significantly exceeded the performance of previously proposed patch level methods or other weakly supervised learning techniques (DSC score: 20 - 70).

“The model developed through this study has greatly improved the performance of weakly supervised learning of pathological images, and it is expected to contribute to improving the efficiency of various studies requiring pathological image analysis,” said Professor Park Sang-Hyun of the Department of Robotics and Mechatronics Engineering at DGIST. “If we can improve the related technology further in the future, it will be possible to use it universally for various medical image zoning issues.”

Related Links:
DGIST 

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TRAcP 5b Assay
TRAcP 5b (BoneTRAP) Assay
New
PSA Test
Humasis PSA Card

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.